SNPS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Synopsys, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / December 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Synopsys, Inc. ("Synopsys" or "the Company") (NASDAQ:SNPS) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants […]

BTDR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bitdeer Technologies Group Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / December 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bitdeer Technologies Group ("Bitdeer" or "the Company") (NASDAQ:BTDR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against

SFM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sprouts Farmers Market, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESS Newswire / December 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sprouts Farmers Market, Inc. ("Sprouts" or "the Company") (NASDAQ:SFM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against

DeFi Crypto Mutuum Finance (MUTM) Advances Through Roadmap Phase 2 with Over $19M in Funding

DUBAI, United Arab Emirates, Dec. 14, 2025 (GLOBE NEWSWIRE) — Mutuum Finance (MUTM) continues to move forward in its development cycle as the project reports progress across Roadmap Phase 2 while total funding has passed the $19M mark. As an Ethereum-based DeFi crypto focused on lending and borrowing infrastructure, Mutuum Finance is now entering a

DeFi Crypto Mutuum Finance (MUTM) Advances Through Roadmap Phase 2 with Over $19M in Funding

DeFi Crypto Mutuum Finance (MUTM) Advances Through Roadmap Phase 2 with Over $19M in Funding GlobeNewswire December 14, 2025 DUBAI, United Arab Emirates, Dec. 14, 2025 (GLOBE NEWSWIRE) — Mutuum Finance (MUTM) continues to move forward in its development cycle as the project reports progress across Roadmap Phase 2 while total funding has passed the

New Crypto Mutuum Finance (MUTM) Reports Phase 6 98% Allocation and Core Protocol Development Ahead of Q4 V1

DUBAI, United Arab Emirates, Dec. 14, 2025 (GLOBE NEWSWIRE) — As the DeFi sector continues to mature, projects that combine visible development progress with growing community participation are starting to stand out. One new altcoin drawing attention is Mutuum Finance (MUTM), which has reported strong advancement across its roadmap while approaching the final stretch of

New Crypto Mutuum Finance (MUTM) Reports Phase 6 98% Allocation and Core Protocol Development Ahead of Q4 V1

New Crypto Mutuum Finance (MUTM) Reports Phase 6 98% Allocation and Core Protocol Development Ahead of Q4 V1 GlobeNewswire December 14, 2025 DUBAI, United Arab Emirates, Dec. 14, 2025 (GLOBE NEWSWIRE) — As the DeFi sector continues to mature, projects that combine visible development progress with growing community participation are starting to stand out. One

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

(HKSE:9969), BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the phase IIb clinical study of novel BTK inhibitor orelabrutinib has met the primary endpoint in patients with systemic lupus erythematosus (SLE). InnoCare has also

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial GlobeNewswire December 14, 2025 BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the

MasterHost Toronto Reports 18% Revenue Increase Following Rollout of Updated AI Pricing Engine

Toronto, Ontario–(Newsfile Corp. – December 14, 2025) – MasterHost Toronto reported an 18 percent increase in average host revenue across its managed portfolio over the twelve months following the rollout of an updated AI pricing engine. The new system, introduced in stages over the past year, is now live across all short-term rental listings managed

Scroll to Top